Role of Macrophage in Inflammation Resolution in Periodontal Patients
The Role of Macrophages in the Inflammatory Resolution Phase in Periodontal Patients
1 other identifier
observational
30
1 country
1
Brief Summary
There is a growing body of evidence to suggest that the resolution of an inflammatory reaction is an active process. This process requiring signals that turn off early inflammatory stages, as neutrophil infiltration and promote resolution phase, as clearance of apoptotic cells. In this array,the relationship between neutrophils, monocytes, and macrophages is crucial for the concert process. Macrophages possess a plasticity of phenotype that explains their protective as well as potentially detrimental role in chronic inflammation and tissue injury. Such heterogeneity arises as macrophages differentiate from monocytes and are exposed to specific tissue- and hematopoietic cell-derived stimuli. It is important to be able to identify the different types of macrophages in this setting. Today's literature can distinguish between 3 main phenotypic groups of macrophages. The classically activated M1 macrophages, the alternatively activated-M2 macrophages and the "resolution phase" - rMs macrophages. The third phenotypic macrophage might play a crucial rule in the resolution phase, and is called the "resolving macrophage". All of those pro-resolving lipid mediators promote the return to tissue homeostasis . The investigators hypothesis is that in periodontal patients the inflammatory process continues because the process does not reach the resolution phase, and in that milieu, the macrophage might be a key component. Within the overall concept of periodontal disease as a model for an inflammatory disease with an stoppable inflammatory reaction, the primary aim of the study is to check the macrophage characteristics in periodontal patients and to compare it to healthy people.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2011
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 25, 2011
CompletedFirst Posted
Study publicly available on registry
June 23, 2011
CompletedStudy Start
First participant enrolled
August 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2012
CompletedJune 23, 2011
June 1, 2011
1 year
May 25, 2011
June 22, 2011
Conditions
Outcome Measures
Primary Outcomes (1)
The macrophage phenotype (M1, M2, resolution phase macrophage)
we will try to specify the characteristics of the macrophage phenotype and to see whether there is a difference between periodontal patients and healthy ones.
1 year
Study Arms (1)
periodontitis
patients diagnosed with periodontal disease
Eligibility Criteria
patients coming to the periodontal clinic in the dental school in order to attend a periodontal treatment
You may qualify if:
- years old and more, male \& female
- generally healthy
- does not take medicine on a regular basis
- has a periodontal disease. control - without a periodontal disease
- no periodontal treatment for at list 6 months prior to his acceptance to the trail
- willing to donate 50 ml of blood twice during the trail
- understands the trail and gave a consent to participate
You may not qualify if:
- pregnancy or nursing
- chronic use of alcohol
- systemic conditions - diseases, neoplastic lesions in the oral cavity
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Periodontal Clinic, Faculty of Dental Medicine, Hebrew University and Hadassah Medical Center
Jerusalem, Israel
Related Publications (1)
Bystrom J, Evans I, Newson J, Stables M, Toor I, van Rooijen N, Crawford M, Colville-Nash P, Farrow S, Gilroy DW. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood. 2008 Nov 15;112(10):4117-27. doi: 10.1182/blood-2007-12-129767. Epub 2008 Sep 8.
PMID: 18779392BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
May 25, 2011
First Posted
June 23, 2011
Study Start
August 1, 2011
Primary Completion
August 1, 2012
Study Completion
August 1, 2012
Last Updated
June 23, 2011
Record last verified: 2011-06